Trial Profile
HPP 593 in dyslipidaemias and diabetes mellitus: phase Ia
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2010
Price :
$35
*
At a glance
- Drugs Mavodelpar (Primary)
- Indications Diabetes mellitus; Dyslipidaemias
- Focus Adverse reactions
- Sponsors High Point Pharmaceuticals
- 08 Nov 2010 New trial record